• 1
    Longstreth GF. Definition and classification of irritable bowel syndrome: current consensus and controversies. Gastroenterol. Clin. North Am. 2005; 34: 17387.
  • 2
    Drossman DA. Introduction. The Rome Foundation and Rome III. Neurogastroenterol. Motil. 2007; 19: 7836.
  • 3
    WHO. International Statistical Classification of Diseases and Related Health Problems, 10th edn. Geneva, Switzerland: World Health Organization, 2007.
  • 4
    Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978; 2 (6138): 6534.
  • 5
    Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. 2002; 97 (11 Suppl.): S726.
  • 6
    DrossmanDA, DouglasA, eds. Rome III: The Functional Gastrointestinal Disorder, 3rd edn. McClean, VA, USA: Degnon Associates, 2006.
  • 7
    Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig. Dis. Sci. 2002; 47: 22535.
  • 8
    Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am. J. Epidemiol. 1995; 142: 7683.
  • 9
    Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005; 34: 20520.
  • 10
    Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005; 34: 24755.
  • 11
    Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol. Clin. North Am. 2005; 34: 281303.
  • 12
    Cash BD, Chey WD. Irritable bowel syndrome—an evidence-based approach to diagnosis. Aliment. Pharmacol. Ther. 2004; 19: 123545.
  • 13
    Park JM, Choi MG, Kim YS et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual. Life. Res. 2009; 18: 43546.
  • 14
    Katsinelos P, Lazaraki G, Kountouras J et al. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. Eur. J. Gastroenterol. Hepatol. 2009; 21: 1839.
  • 15
    Tan YM, Goh KL, Muhidayah R, Ooi CL, Salem O. Prevalence of irritable bowel syndrome in young adult Malaysians: a survey among medical students. J. Gastroenterol. Hepatol. 2003; 18: 141216.
  • 16
    Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment. Pharmacol. Ther. 2004; 20: 33945.
  • 17
    Bommelaer G, Dorval E, Denis P et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol. Clin. Biol. 2002; 26: 111823.
  • 18
    Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates. Dig. Dis. Sci. 1993; 38: 15819.
  • 19
    Danivat D, Tankeyoon M, Sriratanaban A. Prevalence of irritable bowel syndrome in a non-Western population. BMJ (Clin. Res. Ed.) 1988; 296 (6638): 1710.
  • 20
    Kwan AC, Hu WH, Chan YK, Yeung YW, Lai TS, Yuen H. Prevalence of irritable bowel syndrome in Hong Kong. J. Gastroenterol. Hepatol. 2002; 17: 11806.
  • 21
    Drossman DA, Morris CB, Schneck S et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J. Clin. Gastroenterol. 2009; 43: 54150.
  • 22
    Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 114056.
  • 23
    Stewart WF, Liberman JN, Sandler RS et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am. J. Gastroenterol. 1999; 94: 353040.
    Direct Link:
  • 24
    Austin GL, Dalton CB, Hu Y et al. A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2009; 7: 7068.
  • 25
    Jones J, Boorman J, Cann P et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000; 47 (Suppl. 2): ii119.
  • 26
    Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 2009; 104 (Suppl 1): S135.
  • 27
    Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 210831.
  • 28
    Foell D, Wittkowski H, Ren Z et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J. Pathol. 2008; 216: 18392.
  • 29
    Olbe L. Concept of Crohn's disease being conditioned by four main components, and irritable bowel syndrome being an incomplete Crohn's disease. Scand. J. Gastroenterol. 2008; 43: 23441.
  • 30
    Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the ‘no man's land’ of gluten sensitivity. Am. J. Gastroenterol. 2009; 104: 158794.
  • 31
    Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J. Clin. Psychiatry 2001; 62 (Suppl. 8): 2836; discussion 37.
  • 32
    Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr. Opin. Gastroenterol. 2006; 22: 1317.
  • 33
    O'Sullivan M, Clayton N, Breslin NP et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol. Motil. 2000; 12: 44957.
  • 34
    Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeabilityfollowing acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 80411.
  • 35
    Lee V, Guthrie E, Robinson A et al. Functional bowel disorders in primary care: factors associated with health-related quality of life and doctor consultation. J. Psychosom. Res. 2008; 64: 12938.
  • 36
    Dhaliwal SK, Hunt RH. Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective. Eur. J. Gastroenterol. Hepatol. 2004; 16: 11616.
  • 37
    Rosen SD, Paulesu E, Nihoyannopoulos P et al. Silent ischemia as a central problem: regional brain activation compared in silent and painful myocardial ischemia. Ann. Intern. Med. 1996; 124: 93949.
  • 38
    Kern MK, Shaker R. Cerebral cortical registration of subliminal visceral stimulation. Gastroenterology 2002; 122: 2908.
  • 39
    Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J. Clin. Gastroenterol. 2005; 39 (5 Suppl. 3): S184193.
  • 40
    Brehmer A, Croner R, Dimmler A, Papadopoulos T, Schrodl F, Neuhuber W. Immunohistochemical characterization of putative primary afferent (sensory) myenteric neurons in human small intestine. Auton. Neurosci. 2004; 112: 4959.
  • 41
    Nagakura Y, Kontoh A, Tokita K, Tomoi M, Shimomura K, Kadowaki M. Combined blockade of 5-HT3- and 5-HT4-serotonin receptors inhibits colonic functions in conscious rats and mice. J. Pharmacol. Exp. Ther. 1997; 281: 28490.
  • 42
    Mazzia C, Hicks GA, Clerc N. Neuronal location of 5-hydroxytryptamine3 receptor-like immunoreactivity in the rat colon. Neuroscience 2003; 116: 103341.
  • 43
    Taniyama K, Makimoto N, Furuichi A et al. Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine4 receptor, in gastrointestinal motility. J. Gastroenterol. 2000; 35: 57582.
  • 44
    Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J. Neurosci. 1996; 16: 235264.
  • 45
    Coates MD, Mahoney CR, Linden DR et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 165764.
  • 46
    Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009; 9: 15.
  • 47
    Burden S. Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice. J. Hum. Nutr. Diet. 2001; 14: 23141.
  • 48
    McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 2008; 14: 265061.
  • 49
    Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 36778.
  • 50
    Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. J. Med. 2000; 108: 6572.
  • 51
    Lydiard RB, Falsetti SA. Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am. J. Med. 1999; 107 (5A): 65S73S.
  • 52
    Halpert A, Dalton CB, Diamant NE et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am. J. Gastroenterol. 2005; 100: 66471.
    Direct Link:
  • 53
    Kall E, Lindstrom E, Martinez V. The serotonin reuptake inhibitor citalopram does not affect colonic sensitivity or compliance in rats. Eur. J. Pharmacol. 2007; 570: 20311.
  • 54
    Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095103.
  • 55
    Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J. Gastroenterol. 2009; 15: 154853.
  • 56
    Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol. 2002; 35 (1 Suppl.): S5867.
  • 57
    Thompson CA. Novartis suspends tegaserod sales at FDA's request. Am. J. Health Syst. Pharm. 2007; 64: 1020.
  • 58
    Sweetser S, Busciglio IA, Camilleri M et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 296: G295301.
  • 59
    Lang L. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology 2008; 135: 7.
  • 60
    Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313.
  • 61
    Hanauer SB. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev. Gastroenterol. Disord. 2007; 7 (Suppl. 3): S12.
  • 62
    Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980; 79: 12725.
  • 63
    Goldberg PA, Kamm MA, Setti-Carraro P, Van Der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996; 57: 47883.
  • 64
    Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991; 41: 57495.
  • 65
    Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin. Ther. 2008; 30: 884901.
  • 66
    Fayyaz M, Lackner JM. Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther. Clin. Risk Manag. 2008; 4: 418.
  • 67
    Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn. J. Pharmacol. 2001; 86: 2818.
  • 68
    Wallis RM. Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists. Life Sci. 1995; 56: 8618.
  • 69
    Bradesi S, Herman J, Mayer EA. Visceral analgesics: drugs with a great potential in functional disorders? Curr. Opin. Pharmacol. 2008; 8: 697703.
  • 70
    Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 2006; 1: CD004116.
  • 71
    Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998; 280: 15859.
  • 72
    Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment. Pharmacol. Ther. 2004; 19: 2719.
  • 73
    Sallon S, Ben-Arye E, Davidson R, Shapiro H, Ginsberg G, Ligumsky M. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 2002; 65: 16171.
  • 74
    Krueger D, Gruber L, Buhner S et al. The multi-herbal drug STW 5 (Iberogast(R)) has prosecretory action in the human intestine. Neurogastroenterol. Motil. 2009; 21: 1203e110.
  • 75
    Shen YH, Nahas R. Complementary and alternative medicine for treatment of irritable bowel syndrome. Can. Fam. Physician 2009; 55: 1438.
  • 76
    Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment. Pharmacol. Ther. 1988; 2: 10118.
  • 77
    Micklefield G, Jung O, Greving I, May B. Effects of intraduodenal application of peppermint oil (WS(R) 1340) and caraway oil (WS(R) 1520) on gastroduodenal motility in healthy volunteers. Phytother. Res. 2003; 17: 13540.
  • 78
    Lim B, Manheimer E, Lao L et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 2006; 4: CD005111.
  • 79
    Bradesi S, Mayer EA. Novel therapeutic approaches in IBS. Curr. Opin. Pharmacol. 2007; 7: 598604.